Table 3A.
Summary of results from network meta-analysis and traditional pairwise meta-analysis on all-cause death.
| OR 95% CI | Placebo | Dapagliflozin 2.5mg | Dapagliflozin 5mg | Dapagliflozin 10mg | Empagliflozin 10mg | Empagliflozin 25mg | Canagliflozin 100mg | Canagliflozin 300mg |
|---|---|---|---|---|---|---|---|---|
| Placebo | 3.10 (0.26, 47.00) |
0.27 (0.04, 2.70) |
0.94 (0.55, 1.70) |
0.60 (0.22, 1.70) |
0.70 (0.32, 1.70) |
0.82 (0.53, 1.20) |
0.56 (0.12, 2.20) |
|
| Dapagliflozin 2.5mg | 1.67 (0.56, 5.01) |
0.09 (0.01, 0.70) |
0.41 (0.01, 4.30) |
|||||
| Dapagliflozin 5mg | 0.66 (0.24, 1.81) |
0.40 (0.10, 1.50) |
1.50 (0.13, 17.00) |
|||||
| Dapagliflozin 10mg | 0.93 (0.83, 1.04) |
0.56 (0.19,1.67) |
1.40 (0.51, 3.85) |
|||||
| Empagliflozin 10mg |
0.70 (0.58, 0.85) |
0.42 (0.14, 1.28) |
1.06 (0.38, 2.96) |
0.75 (0.60, 0.95) |
||||
| Empagliflozin 25mg |
0.69 (0.57, 0.84) |
0.41 (0.14, 1.26) |
1.04 (0.37, 2.91) |
0.74 (0.59, 0.93) |
0.98 (0.79, 1.22) |
|||
| Canagliflozin 100mg |
0.83 (0.73, 0.95) |
0.50 (0.16,1.50) |
1.25 (0.45, 3.46) |
0.89 (0.75, 1.06) |
1.18 (0.93, 1.50) |
1.20 (0.95, 1.53) |
||
| Canagliflozin 300mg | 0.66 (0.40,1.08) | 0.39 (0.12,1.31) |
0.99 (0.32, 3.05) |
0.71 (0.43, 1.18) |
0.94 (0.55, 1.60) |
0.95 (0.56, 1.63) |
0.79 (0.48, 1.31) |